Generics Makers Challenge AstraZeneca In Crestor MDL

By Samuel Howard

Law360, New York (January 28, 2010, 3:54 PM ET) -- Teva Pharmaceuticals USA Inc., Apotex Corp. and a clutch of other generic-drug makers accused of infringing AstraZeneca PLC’s patent for the cholesterol drug Crestor are claiming the company's marketing unit lacks standing to partake in the multidistrict litigation.

On Wednesday the defendants urged Judge Joseph J. Farnan Jr. of the U.S. District Court for the District of Delaware to jettison AstraZeneca Pharmaceuticals LP, contending that unlike the other three plaintiffs, the entity merely markets the drug and has no proprietary rights in the patent-at-issue.

While the...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles